Archive for the 'Radiation' Category
June 26th, 2007. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma
Conclusions: Prophylactic drain site radiotherapy in malignant pleural mesothelioma does not reduce the incidence of tumour seeding by the margin indicated by previous studies.
June 7th, 2007. An association between postoperative radiotherapy for primary breast cancer in 11 National Surgical Adjuvant Breast and Bowel Project (NSABP) studies and the subsequent appearance of pleural mesothelioma
Conclusions: There appears to be a small but statistically significant increased risk of developing mesothelioma following radiotherapy administered for primary breast cancer. However, in absolute numbers, the risk is too small to be considered a contraindication to administering radiotherapy when indicated.
May 4th, 2007. Malignant mesothelioma following thoracic radiotherapy for lung cancer
Opacification of the lung field from prior therapy made determination of the diagnosis more challenging. Secondary malignancies such as mesothelioma should be considered in patients who develop unexplained symptoms even long after treatment of a primary tumor.
May 1st, 2007. Dose-Dependent Pulmonary Toxicity After Postoperative Intensity-Modulated Radiotherapy for Malignant Pleural Mesothelioma
Conclusion: The results of our study have shown that fatal pulmonary toxicities were associated with radiation to the contralateral lung. V20 was the only independent determinant for risk of PRD or non–cancer-related death. The mean V20 of the non-PRD patients was considerably lower than that accepted during standard thoracic radiotherapy, implying that the V20 should be kept as low as possible after extrapleural pneumonectomy.
April 17th, 2007. A large abdominal wall mass as an initial manifestation of malignant mesothelioma
Despite further radiotherapy, the patient died of cardiac tamponade due to tumor invasion 38 months after the initial diagnosis. To the best of our knowledge, this is the first description of malignant mesothelioma presenting via initial invasion of the abdominal wall without changes in the thoracic space.
April 13th, 2007. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma
Conclusions: The observed rate of operability is promising. A median survival of 23 months for patients undergoing EPP compares favourably with the survival reported from single center studies of upfront surgery. This approach was not associated with an increase in psychological distress.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Extrapleural Pneumonectomy (EPP), Full Archive, Gemcitabine (Gemzar), Pleural, Radiation, Surgery, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
April 6th, 2007. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial
Conclusion: Induction chemotherapy with gemcitabine and cisplatin followed by EPP and adjuvant RT for locally advanced MPM is feasible and leads to a better median overall survival than that previously reported with EPP and RT alone.
Posted in Chemotherapy, Cisplatin (Platinol ®), Extrapleural Pneumonectomy (EPP), Full Archive, Gemcitabine (Gemzar), Pleural, Radiation, Surgery, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
April 6th, 2007. Four-Modality Therapy in Malignant Pleural Mesothelioma: A Phase II Study
Conclusion: The four-modality treatment that we adopted for advanced-stage MPM was feasible, well tolerated by most of the patients, and produced a favorable median survival. This treatment approach warrants further investigation.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Full Archive, Gemcitabine (Gemzar), Pleural, Pleurectomy/decortication, Radiation, Surgery, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
April 4th, 2007. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results
Conclusions: In MPM, the combined modality approach using the Carboplatin/Gemcitabine combination as induction chemotherapy is feasible, with good results in terms of survival and morbidity. Our results are similar to those of other studies using a heavier modality treatment.
Posted in Carboplatin, Determining Efficacy, Extrapleural Pneumonectomy (EPP), Full Archive, Gemcitabine (Gemzar), Pleural, Radiation, Surgery, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
March 31st, 2007. Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests
Conclusion: Inhibition of survivin and Aurora B induces mitotic cell arrest in mesothelioma cells after irradiation. These two proteins may be potential therapeutic targets for the enhancement of radiotherapy in malignant pleural mesothelioma.
March 28th, 2007. Retroperitoneal malignant schwannoma and peritoneal malignant mesothelioma: a case report
Singlemodality therapy of these tumors has shown poor results. Combined-modality approaches have shown some benefits, but further studies are required.
March 16th, 2007. The role of radiotherapy in the treatment of malignant pleural mesothelioma
There is no role for radical radiotherapy alone, but the role of radiotherapy as part of multimodality therapy is discussed. There have been studies of intensity-modulated radiotherapy as part of multimodality therapy and this technique needs to be evaluated further.
February 23rd, 2007. Therapeutic radiation for lymphoma: risk of malignant mesothelioma
Conclusions: Mesothelioma rates for patients who had received radiotherapy were increased for survivors of HL and NHL. No increases were observed among the unirradiated. These findings and the existing body of supporting studies confirmed that radiotherapy is a cause of mesothelioma. Cancer 2007.
December 26th, 2006. A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma
Conclusions: The multimodality treatment we adopted for stage II-III MPM was feasible, well tolerated by most of the patients and produced a favourable outcome. New targeted therapies are awaited for further improvements in the treatment of this disease.
Posted in Biphasic or Mixed, Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Epithelioid, Full Archive, Gemcitabine (Gemzar), Intrapleural Chemotherapy, Pleural, Pleurectomy/decortication, Pneumonectomy, Radiation, Sarcomatoid, Surgery, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
November 3rd, 2006. Hyperthermia combined with intra-thoracic chemotherapy and radiotherapy for malignant pleural mesothelioma
Conclusion: It was therefore concluded that hyperthermia combined with intra-thoracic chemotherapy using cisplatinum or carboplatinum may be tolerable. This approach appears effective and more acceptable for patients with MPM with pleural effusion than other multi-modality therapy.
November 3rd, 2006. Radiation-Induced Cellular DNA Damage Repair Response Enhances Viral Gene Therapy Efficacy in the Treatment of Malignant Pleural Mesothelioma
Conclusions: RT can be combined with oncolytic herpes simplex virus therapy in the treatment of malignant pleural mesothelioma to achieve synergistic efficacy while minimizing dosage and toxicity.
November 1st, 2006. Malignant pleural mesothelioma: a comprehensive review
Conclusions: The disease is expected to increase in incidence till 2020, so awareness of this entity as a possible diagnosis should be heightened. In patients with advanced disease, several newer antitumor agents are already showing a capability of extending survival so it is not unreasonable to expect further progress in this area.
Posted in Determining Efficacy, Diagnosis & Differentiation, Extrapleural Pneumonectomy (EPP), Full Archive, General, New & Novel, Pleurectomy/decortication, Radiation, Surgery, Treatment, Type of Assessment: | No Comments »
October 24th, 2006. Feasibility of Boron Neutron Capture Therapy (BNCT) for malignant pleural mesothelioma from a viewpoint of dose distribution analysis
Conclusions: From a viewpoint of the dose–distribution analysis, BNCT has the possibility to be a promising treatment for MPM patients who are inoperable because of age and other medical illnesses.
October 3rd, 2006. Dosimetric verification for intensity-modulated radiotherapy of thoracic cancers using experimental and Monte Carlo approaches
Conclusion: The Pinnacle and Corvus dose calculations were acceptable for thoracic IMRT in high-dose regions. Beam modeling is likely the most critical factor for the accuracy of IMRT dose calculations.
|
|  |
